Aytu Biopharma (AYTU) Total Non-Current Liabilities (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Total Non-Current Liabilities data on file, last reported at $16.6 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 10.88% year-over-year to $16.6 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 10.88% decrease from a year earlier, with the FY2025 full-year figure at $42.1 million, up 49.72% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $16.6 million, down from $42.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for AYTU reached as high as $104.7 million in Q1 2023 and fell as low as $14.4 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $51.1 million across 5 years, with a median of $35.8 million in 2025.
• Across the five-year window, Total Non-Current Liabilities tumbled 86.25% in 2024 and surged 97.24% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $85.8 million in 2022, then slumped by 60.15% to $34.2 million in 2023, then tumbled by 37.4% to $21.4 million in 2024, then soared by 97.24% to $42.2 million in 2025, then plunged by 60.76% to $16.6 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $16.6 million in Q1 2026, $42.2 million in Q4 2025, and $35.8 million in Q3 2025.